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Background: Marine food is an important source of omega-3 fatty acids with beneficial health effects. Oils from
marine organisms have different fatty acid composition and differ in their molecular composition. Fish oil (FO) has a
high content of eicosapentaenoic and docosahexaenoic acids mainly esterified to triacylglycerols, while in krill oil
(KO) these fatty acids are mainly esterified to phospholipids. The aim was to study the effects of these oils on the
lipid content and fatty acid distribution in the various lipid classes in liver and brain of mice.
Methods: Mice were fed either a high-fat diet (HF), a HF diet supplemented with FO or with KO (n = 6). After six
weeks of feeding, liver and brain lipid extracts were analysed using a shotgun and TAG lipidomics approach.
Student t-test was performed after log-transformation to compare differences between study groups.
Results: Six weeks of feeding resulted in significant changes in the relative abundance of many lipid classes
compared to control mice. In both FO and KO fed mice, the triacylglycerol content in the liver was more than
doubled. The fatty acid distribution was affected by the oils in both liver and brain with a decrease in the
abundance of 18:2 and 20:4, and an increase in 20:5 and 22:6 in both study groups. 18:2 decreased in all lipid
classes in the FO group but with only minor changes in the KO group. Differences between the feeding groups
were particularly evident in some of the minor lipid classes that are associated with inflammation and insulin
resistance. Ceramides and diacylglycerols were decreased and cholesteryl esters increased in the liver of the KO
group, while plasmalogens were decreased in the FO group. In the brain, diacylglycerols were decreased, more by
KO than FO, while ceramides and lactosylceramides were increased, more by FO than KO.
Conclusion: The changes in the hepatic sphingolipids and 20:4 fatty acid levels were greater in the KO compared
to the FO fed mice, and are consistent with a hypothesis that krill oil will have a stronger anti-inflammatory action
and enhances insulin sensitivity more potently than fish oil.
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Marine omega-3 fatty acids are well known for a range
of documented health benefits [1]. Omega-3 polyunsat-
urated fatty acids (PUFAs) such as eiocosapentaenoic
acid (EPA) and docosahexaenoic acid (DHA) are bio-
active dietary compounds that are found particularly in
marine-derived food sources such as fatty fish, seaweed,
shellfish, microalgae and krill. Marine oils differ in their
fatty acid composition and lipid structure, although EPA* Correspondence: jon.skorve@k2.uib.no
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article, unless otherwise stated.and DHA are the predominant fatty acids. Most fish oils
(FOs) on the market today have their omega-3 PUFAs in-
corporated into triacylglycerols (TAGs) or in ethyl esters.
Krill oil (KO), extracted from Antarctic krill (Euphausia
superba), has a unique chemical composition and contains
astaxanthin, which due to its anti-oxidative effect, might
enhance the stability of the omega-3 PUFAs in the oil and
thereby preserve them from lipid oxidation [2, 3]. Like
FO, it is rich in omega-3 PUFAs, but the fatty acids (FAs)
are mainly incorporated into phospholipids (PLs) rather
than TAGs, with some content of un-esterified fatty acids.
This may be biologically and therapeutically significant,
since PL FAs are well-absorbed by the intestine andle is distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Fat content and fatty acid composition of the diets
High fat control Fish Oil (FO) Krill Oil (KO)
Fat source (% in diet)
Lard 21,3 % 15,7 % 15,6 %
Soy oil 2,3 % 2,3 % 2,3 %
Fish/krill oil 5,8 % 5,6 %
Fatty acids (% of total
fatty acids in diet)
Total SFA 42,9 % 34,1 % 39,7 %
Total MUFA 38,7 % 32,1 % 35,4 %
Total ω6 16,4 % 14,5 % 14,6 %
EPA 0,03 % 9,0 % 5,2 %
DHA 0,05 % 6,4 % 2,3 %
The content of EPA and DHA in the KO diet was about half of the FO diet
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fatty acids, whether being presented as a part of TAG
molecules (like in FO) or incorporated into PL mole-
cules (as in KO), are capable of influencing different
metabolic pathways [8] and differently modulate
physiological effects [9]. However, also specific PLs may
have distinct properties in relation to bioavailability, in-
testinal absorption and stability, which may be of im-
portance in relation to benefits for metabolic health
[10]. The structural differences in the PUFA-rich lipid
molecules may affect tissue uptake and the distribution
of fatty acids in cellular lipid fractions and thereby
promote different regulatory effects on lipid homeosta-
sis [11, 12].
We have previously conducted a study to investigate
the metabolic effects in mice when two of the major
sources of omega-3 supplements, FO and KO, were
supplemented to a Western-like high-fat diet. Equal
amounts of FO and KO (6 % by weight) were added to
the diet, and the effects on plasma and liver lipids as
well as gene regulation in liver and intestine were inves-
tigated [13]. In spite of a lower omega-3 fatty acid con-
tent in the KO supplemented diet, plasma and liver PLs
omega-3 levels were similar in the two groups, indicat-
ing a higher bioavailability of omega-3 fatty acids from
KO. Moreover, feed containing either FO or KO pro-
moted different gene expression profiles in liver and in-
testine with FO causing an apparent PPARα response,
while KO supplementation rather acted as a negative
regulator of endogenous cholesterol and fatty acid syn-
thesis. It was concluded from this study that both FO
and KO promote lowering of plasma lipids and regulate
lipid homeostasis, but with different efficacy and par-
tially via different mechanisms. To further explore the
mechanistic basis for these differences between the two
oils, we have here conducted a comprehensive lipidomic
analysis of livers from these mice. Omega-3 fatty acids
as well as astaxanthin are stated to have important func-
tions also in the brain as neuroprotectors during inflam-
mation and oxidative stress [for reviews, see refs 14, 15].
We therefore analyzed the effects of omega-3 PUFA’s
provided as FO and KO on the fatty acid composition
also in brain lipids with special focus on DHA, which is
considered to have important functions in the brain.
This analysis showed that feeding mice with either FO
or KO differentially affected the lipid and fatty acid com-
position in liver and brain.
Results
Body weight and feed intake
The amount of FO and KO in the diets were approxi-
mately the same. However, the FO contained more
omega-3 FAs than the KO with EPA and DHA levels ap-
proximately twice as high as in the KO diet (Table 1).The basic outcomes such as food intake, body weights
and plasma lipids were recently reported [13]. The final
weights of the mice were not significantly different be-
tween the three study groups. Also the feed intake in the
two marine oil diet groups was similar in comparison
with the control group.
Distribution of lipid classes in liver and brain
After 6 weeks, relative hepatic TAG content showed a
significant nearly 2-fold increase in both FO and KO fed
animals as compared to control mice (Table 2 and Fig. 1).
This increase affected the relative distribution of the
lipid classes, and therefore, the distribution of the lipid
classes are reported both as concentration and mole per-
centages for liver (Table 2) and brain (Table 3).
PLs constitute the main lipid class in the liver, with
phosphatidylcholines (PCs) and phosphatidylethanol-
amines (PEs) being the main PL species (Table 2). PC
(concentration or mole %) did not show any difference
between the groups, but total PE and phosphatidylinositol
(PI) concentrations were slightly decreased in both FO
and KO groups (Fig. 1a). However, the relative abundance
of PE and PI were both significantly decreased in both diet
groups due to the increases in TAGs (Fig. 1b). In general
the differences between the diet groups were small,
however, the ether phospholipids PC P and PE O were
both decreased in the FO mice, while slightly increased
in the KO mice with the absolute and relative concen-
trations being significantly lower in the FO group com-
pared to KO (Fig. 1a, b). Also, the concentrations of
LPE and LPC were significantly increased in KO mice
but not in FO mice.
Cholesteryl esters were more than doubled in KO
supplemented mice but only slightly increased in FO
mice (Fig. 1a, b). Also for the diacylglyerol (DAG) lipids
there was a distinct difference between the two study
groups with the relative abundance of total DAGs being
Table 2 Concentration and mole percentage of lipid classes in liver
Concentration (pmol/ug tissue) Mol %
Control Fish Oil (FO) Krill Oil (KO) Control Fish Oil (FO) Krill Oil (KO)
Lipid class Average SD Average SD Average SD Average SD Average SD Average SD
CE 0,287 0,116 0,477 0,297 0,776 0,371 1,8 0,7 2,3 1,1 4,1 2,3
DAG 0,495 0,163 0,714 0,399 0,330 0,067 3,1 0,8 3,4 1,1 1,7 0,3
PC 7,454 2,215 8,097 1,926 7,550 1,762 46,2 5,8 41,1 4,1 39,2 9,3
PE 1,853 0,421 1,546 0,500 1,669 0,255 11,8 1,5 7,9 1,7 8,7 1,2
PG 0,039 0,011 0,039 0,011 0,032 0,011 0,2 0,0 0,2 0,0 0,2 0,1
PI 0,115 0,023 0,108 0,029 0,103 0,034 0,7 0,1 0,6 0,1 0,5 0,2
PS 0,780 0,379 1,129 0,298 1,158 0,333 4,8 1,5 5,8 1,1 6,0 1,6
PC O 0,238 0,054 0,360 0,093 0,374 0,114 1,5 0,2 1,8 0,2 1,9 0,6
PC P 0,059 0,018 0,039 0,012 0,077 0,024 0,4 0,1 0,2 0,1 0,4 0,1
PE O 0,018 0,005 0,008 0,003 0,020 0,005 0,1 0,0 0,0 0,0 0,1 0,0
PE P 0,029 0,006 0,035 0,014 0,025 0,012 0,2 0,0 0,2 0,0 0,1 0,1
LPC 0,110 0,027 0,161 0,038 0,156 0,022 0,7 0,1 0,8 0,2 0,8 0,1
LPE 0,014 0,005 0,019 0,007 0,025 0,008 0,1 0,0 0,1 0,0 0,1 0,0
LPI 0,003 0,001 0,003 0,001 - - - - - - - -
SM 0,216 0,049 0,271 0,085 0,245 0,075 1,4 0,2 1,4 0,4 1,3 0,3
Cer 1,439 0,275 1,208 0,276 1,431 0,238 9,4 2,3 6,5 2,8 7,4 0,9
Glc/GalCer 0,613 0,125 0,673 0,176 0,332 0,051 4,0 1,2 3,5 1,3 1,8 0,4
LacCer 0,013 0,004 0,023 0,011 0,014 0,004 0,1 0,0 0,1 0,1 0,1 0,0
Gb3 0,015 0,004 0,014 0,004 0,011 0,003 0,1 0,0 0,1 0,0 0,1 0,0
TAG 2,158 1,109 5,145 3,012 5,021 2,725 13,3 5,4 24,0 8,7 25,6 12,9
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increased in the FO group with the relative concentra-
tion being significantly different between FO and KO
(Fig. 1a, b).
All the ceramides, except lactosylceramide (LacCer)
showed a decreasing trend in their relative abundance in
both FO and KO fed mice. For glucosyl/galactosylcera-
mides the decrease was particularly large in the KO mice
(nearly 60 %), and also globotriaosylceramides (Gb3s)
showed a statistically significant decrease. The abundance
of LacCer changed in opposite directions with a 40 %
increase in the FO group and 20 % decrease in the KO
group, although the differences were not significant
(Fig. 1b).
Brain contains about 25 % of the body’s cholesterol of
which almost all is unesterified. Here we only analyzed
esterified cholesterol, which was essentially unchanged
in both oil groups. The dominating lipid class was PCs,
constituting approximately 60 mole percent of total
lipids, while PSs constituted approximately 16–18 mole
percent (Table 3). TAGs were not analyzed as their
abundance in brain is very low, however DAG was
significantly decreased in KO (Fig. 1c). There were only
small changes in the levels of the major lipid classes,
but total Cer and LacCer, which form minor lipidcomponents in the brain, were increased in FO (Fig. 1c).
There was a trend (but not significantly different)
towards opposite regulation in e.g., lysophosphatidyli-
nositol (LPI), phosphatidic acid (PA) and PE P.
Distribution of fatty acids and lipids in liver
The lipidomic approach identifies lipid species, however,
due to the analytical challenge of identification of mo-
lecular TAG species, TAG lipids are reported as the
sum of C-atoms and double bonds (i.e., TAG 52:3 con-
tains a mixture of TAG (16:0/18:1/18:2) and TAG
(16:1/18:1/18:1)). Figure 2 summarizes the changes in
fatty acid composition of some of the most common
lipid species in liver. As expected, the relative content
of the polyunsaturated n-3 fatty acids EPA (20:5) and
DHA (22:6) was strongly increased in e.g., PC, TAG, PE
and CE (Fig. 2a, b). The increases were largest in PC,
PE and TAG for EPA (about 50-fold) with the effect being
strongest with FO. The effects of FO and KO were very
similar with the difference between the FO and KO being
rather small compared to the overall changes caused by
marine oil feeding. DHA was increased in several lipid
classes, i.e., CE, PC, PC O, PS and TAG, although the
increase in DHA was less evident compared to EPA
(Fig. 2b). The increased concentrations of EPA and DHA
Fig. 1 Relative differences in liver and brain lipid classes. Differences between FO, KO and control mice based on a concentration in liver, b mole
percentage in liver and c concentration in brain. *** p < 0.001, ** p < 0.01, * p < 0.05
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18:2, 18:3 and 20:4 (Fig. 2c). The total levels of 18:2, 18:3
and 20:4 were decreased by FO whereas only total 20:4
was decreased by KO. In PC, PE, PC O, PC P and PE O
the decrease in 18:2 was significant in the FO group. In
the KO mice the changes were minor with 18:2 being in-
creased in CE and decreased in DAG only. Total 18:3 and
18:3 in PC was decreased by FO while 20:4 was decreased
in most PL classes in both groups with the effect being
stronger with KO.
As shown in Fig. 1a, the total level of CE was in-
creased more in KO than in FO mice, while CE 20:5and 22:6 were increased to similar extent in both
groups (Fig. 2a, b). The increased level of CE in KO is
mainly due to larger increases in SFA and MUFA CEs,
such as CE 16:0, CE 16:1 (Figs. 3a and 4). At the
molecular level, the most significantly affected lipids
were PC 16:0/20:5 and PE 18:0/20:5 (Fig. 3a). TAGs
containing SFAs and MUFAs were increased only in
the FO group while PUFA-containing TAGs were in-
creased in both groups (Fig. 3a). Figure 3b summarizes
the most strongly (p < 0.01) regulated lipids between
FO and KO. Several 18:2 containing lipids and ether
phospholipids were lower in the FO group, whereas
Table 3 Concentration and mole percentage of total lipid classes in brain
Concentration (pmol/ug tissue) Mol %
Control Fish Oil (FO) Krill Oil (KO) Control Fish Oil (FO) Krill Oil (KO)
Lipid class Average SD Average SD Average SD Average SD Average SD Average SD
CE 0,049 0,006 0,055 0,010 0,048 0,006 0,2 0,0 0,2 0,0 0,2 0,0
DAG 0,149 0,040 0,122 0,030 0,102 0,017 0,5 0,1 0,4 0,1 0,4 0,1
PC 18,503 1,473 18,891 1,964 16,771 0,890 60,5 2,0 58,9 4,2 59,3 2,1
PE 2,262 0,204 2,169 0,447 1,942 0,277 7,4 0,8 6,7 1,0 6,9 1,0
PG 0,082 0,012 0,079 0,024 0,071 0,019 0,3 0,0 0,2 0,1 0,3 0,1
PI 0,196 0,032 0,183 0,031 0,166 0,026 0,6 0,1 0,6 0,1 0,6 0,1
PS 4,923 0,649 5,754 1,063 4,935 0,525 16,1 1,1 17,8 2,1 17,4 1,5
PC O 0,073 0,035 0,064 0,011 0,073 0,022 0,2 0,1 0,2 0,0 0,3 0,1
PC P 0,089 0,013 0,089 0,012 0,083 0,014 0,3 0,0 0,3 0,0 0,3 0,0
PE O - - 0,012 0,002 0,011 0,002 - - 0,0 0,0 0,0 0,0
PE P 1,957 0,464 2,199 0,459 1,855 0,194 6,3 1,1 6,8 1,1 6,6 0,8
LPC 0,032 0,008 0,028 0,006 0,031 0,005 0,1 0,0 0,1 0,0 0,1 0,0
LPE 0,011 0,005 0,012 0,003 - - - - - - - -
LPG 0,048 0,024 - - - - 0,2 0,1 - - - -
LPI 0,025 0,013 0,020 0,007 0,029 0,007 0,1 0,0 0,1 0,0 0,1 0,0
SM 1,448 0,141 1,545 0,169 1,400 0,171 4,8 0,7 4,8 0,2 4,9 0,6
Cer 0,080 0,029 0,136 0,020 0,105 0,026 0,3 0,1 0,4 0,0 0,4 0,1
Glc/GalCer 0,571 0,114 0,655 0,102 0,555 0,107 1,9 0,3 2,1 0,4 2,0 0,4
LacCer 0,022 0,002 0,027 0,004 0,025 0,005 0,1 0,0 0,1 0,0 0,1 0,0
Skorve et al. Lipids in Health and Disease  (2015) 14:88 Page 5 of 12glucosylceramides (GlcCer) were increased in the FO
group as compared to the KO group.
Figure 4 summarizes the changes in lipids containing
SFAs and MUFAs. There was an increase in the abun-
dance of SFA containing LPC, LPE, PC O, PE O and PS,Fig. 2 Relative differences in liver concentrations of polyunsaturated fatty a
for the following fatty acids 20:5 (a), 22:6, (b), 18:2, 18:3 and 20:4 (c). *** p <with small differences between the study groups. For
MUFA-containing lipids, statistically significant in-
creases were observed in LPC, PC P, PE O and PS in the
KO group, while a decrease in PE was observed in the
FO group.cids. Differences in liver lipid classes between FO, KO and control mice
0.001, ** p < 0.01, * p < 0.05
Fig. 3 Relative differences in liver lipids which show a statistically significant change. a Lipids with a statistically significant relative difference > 250 in
either FO or KO group as compared to the control group. b Lipids that had p-value < 0.01 between the FO and KO groups. *** p < 0.001, ** p < 0.01,
* p < 0.05
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Significant changes could be observed for specific lipids
in brain, although the changes in the abundance of the
major lipid classes were small. Figure 5 summarizes the
changes that were significantly different by FO or KO.
CE 20:5 increased by both FO and KO, and, surprisingly,
the concentration of CE 20:5 (which is the main CE in
brain) was about 20 times higher than CE 22:6 in brain
in the HF fed mice. Both CEs were increased by FO and
KO, and although CE 22:6 increased more (about 2-fold)
than CE 20:5 (about 20 %) (Fig. 6a), 20:5 remained the
main CE species in brain. FO decreased CE 18:1 and
20:4 and of interest to note is that only 20:5 and 22:6
CEs were detected in KO fed mice, the other CEs being
below the detection level. The fatty acid profile as well
as regulation of CE in liver and brain is markedly differ-
ent with e.g., CE 18:1 and 18:2 being increased by KO
in liver (Fig. 6a). Several of the Cer fatty acid species in
brain increased significantly by FO, while the increases
in KO were weaker and not significant (Fig. 5). Several
PLs (PC, PE, PE P/PE O and PS), in particular containing
20:4, were decreased in both groups with the exception of
22:5 and 22:6 containing PE P species that were increased
in particular in the FO group. DAG 18:0/18:2, PC16:0/
22:4, PI 16:0/20:4, PS 18:0/20:4, PS 20:4/20:4 and SM
(d18:1/21:1) (d18:1/20:2-OH) decreased in both groups,but significantly only in KO group (Fig. 5). 20:5 was not
detected in PL in the control mice, but trace amounts
were detected in the FO and KO mice, whereas 22:6 was
much more abundant in several PL. 20:5 was not detected
in any PE P species, but 22:5 and 22:6 were increased by
FO and KO in some ether-linked PE Ps (PE P-18:0/22:5
(PE O-18:1/22:5) and PE P-18:1/22:6, Fig. 5).
Discussion
Fish oil and krill oil are both abundant in omega-3
fatty acids but the relative content of the main fatty
acid species and the molecular composition are differ-
ent. How these differences affect the metabolic re-
sponse, and in particular the lipid composition, in
animals fed with these oils has not been clarified. The
lipidomic analyses presented herein show similar
changes in the hepatic content of the main lipid
classes between the two oils and in both intervention
groups an accumulation of hepatic TAGs was ob-
served, with an accompanying decrease in the relative,
but not absolute, levels of several PL classes. This
confirms the observations reported in the previous
paper from this study [13] where small, but not
significant differences were observed in plasma and
hepatic lipids between mice fed either FO or KO. The
data presented here extends these findings with a
Fig. 4 Relative differences in liver concentrations of saturated (SFA) and monounsaturated (MUFA) fatty acids. Differences in liver lipid classes
between FO, KO and control mice. *** p < 0.001, ** p < 0.01, * p < 0.05
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and showing in particular some noteworthy differ-
ences in the minor lipids.
The changes in the hepatic composition of the main
fatty acids were grossly a reflection of the higher con-
tent of omega-3 fatty acids in the oil containing feeds
compared to the control feed. The abundance of 20:5
and 22:6 were increased in both intervention groups,
but more in the FO than the KO group. This is likely a
reflection of the respective feed compositions (lower
omega-3 FA content in the KO diet), but the difference
in abundance of these fatty acids is smaller than ex-
pected since the difference in the omega-3 content be-
tween these feeds are prominent [Table 1]. The relative
increase was highest for 20:5, which is expected consid-
ering the very low hepatic level in the control mice and
high content in the oils. The increased abundance of
the omega-3 fatty acids was at the expense of other
polyunsaturated fatty acids, with the decrease being
particularly noteworthy for 18:2 and 20:4. In accord-
ance with the highest increase in the relative content of
omega-3 fatty acids in the FO mice, the decrease in18:2 in PL and ether phospholipids (PC O, PC P, PE O)
was larger in this group compared to the KO group. In
contrast, the decreased abundance of 20:4 was largest
in the KO fed mice (Fig. 2c). Arachidonic acid metabo-
lites are key inflammatory intermediates and the lower
level of this fatty acid in the KO fed mice indicate that
KO may have a greater anti-inflammatory action than
FO [16].
The observed increase in TAG species was dependent
on their fatty acid composition, and was particularly
large (up to15 fold) for TAG species containing the lon-
ger polyunsaturated FAs, particularly EPA and DHA
(Fig. 2). For these species FO tended to result in a lar-
ger increase than KO. For other TAG species contain-
ing mono and di-unsaturated fatty acids and saturated
FAs the increase in concentration was much smaller
but still with the highest increase in the FO fed mice
(Fig. 3a). This is consistent with the smaller decrease in
18:1 and 18:2 in the KO fed mice and a higher lipogen-
esis in the FO fed compared to the KO fed mice. In-
deed, data that have been published from this study
[13] showed a decreased lipogenesis and lower plasma
Fig. 5 Relative differences in concentrations of brain lipids. Lipids that showed statistically significanct changes in any of the comparisons
between FO, KO and control mice are shown. ** p < 0.01, * p < 0.05
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mice.
Differences between the intervention groups were
particularly evident in some of the minor lipid classes,
such as diacylglycrols, sphingolipids and plasmalogens,
molecules that are associated with e.g., inflammation
and insulin resistance. Sphingolipids have emerged as
bioactive lipids with complex cellular functions, includ-
ing roles in cell signaling as well as important structural
roles in cellular membranes. Many sphingolipids have
been shown to regulate cell growth, adhesion, migration,
inflammation and intracellular trafficking [17, 18]. Cer is
one of the component lipids making up sphingomyelin
that play important roles as intracellular signaling mol-
ecules. Several lines of data indicate that the develop-
ment of insulin resistance is associated with tissue
accumulation of specific Cer species as well as accumu-
lation of DAG [19–24]. DAGs are metabolites that have
intracellular signaling properties, and hepatic insulin
resistance have been reported to be associated with an
increase in hepatic DAG content. The link between
hepatic DAG accumulation and hepatic insulin resist-
ance could be attributed to activation of PKCε, the
predominant PKC isoform activated in liver followingfat feeding. This mechanism is similar to the action of
ceramides, which directly activate the PKCζ isoform
that phosphorylates and inhibits the translocation of
Akt/PKB, and thereby inhibits insulin signal transduc-
tion [19, 24, 25]. In our study the ceramides, especially
GlcCer, were decreased significantly more in the krill
oil compared to the fish oil group (Fig. 1). A similar
trend was observed also for the hepatic DAG content.
The abundance of DAG was decreased in the KO group
and unchanged in the FO group (Fig. 1). Decreased accu-
mulation of hepatic DAG and ceramides may be related
to a reduced flux of especially saturated fatty acids. Cer
synthesis is dependent on the availability of long-chain
saturated FAs and excessive levels of free fatty acids
stimulate the accumulation of Cer and various Cer me-
tabolites, such as GlucCer and LacCer [20]. As reported
previously, lipogenesis and plasma FFA levels seem to
be decreased in the KO fed mice compared to the FO
fed mice [13], which both could contribute to decreased
synthesis of DAG, Cer and GlcCer. The decreased
abundance of DAG and GlcCer in the KO fed com-
pared to the FO fed mice may indicate that KO has a
greater anti-inflammatory potential and a more benefi-
cial effect on insulin sensitivity than FO.
Fig. 6 Comparison of relative differences in liver and brain lipids. Differences in a cholesteryl esters and b ceramides between FO, KO and control
mice. ** p < 0.01, * p < 0.05
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synthases (CerS) that differ in substrate specificity and
tissue distribution. In this study most Cer were in-
creased up to 2-fold in the brain but generally de-
creased in liver (Fig. 6), which may have physiological
implications. The ceramide synthase 2 (CerS2) catalyzes
synthesis of long-chain (22:0, 24:0, 24:1) Cer, and
reduction in these ceramides is associated with neuro-
degenerative disorders including epilepsy [26]. A de-
crease in CerS2 activity in liver leads to compensatory
increases in long-chain C16-ceramides that confers sus-
ceptibility to diet-induced steatohepatitis and insulinresistance [27]. C16-ceramides also promote weight
gain and glucose intolerance [28]. However, there was a
general trend towards decrease in all Cer species in
liver. On the other hand, increased C16-ceramides in
hypothalamus may promote lipotoxicity and ER-stress
leading to sympathetic inhibition, reduced brown adi-
pose tissue thermogenesis and weight gain [29].
Regarding LacCer the picture was slightly different. It
is believed that a number of pro-inflammatory factors
activate lactosylceramide synthase to generate LacCer,
which in turn affect inflammatory states and processes
such as adhesion and angiogenesis [30]. The FO fed
Skorve et al. Lipids in Health and Disease  (2015) 14:88 Page 10 of 12mice showed an increased content of LacCer, indicating
that FO, in contrast to KO, may induce pro-inflammatory
factors even if the synthesis of anti-inflammatory pros-
taglandins are increased by omega-3 fatty acids.
Increased lipid oxidation accompanies pathological
states such as type II diabetes and cardiovascular dis-
eases that is associated with decreased plasmalogen
levels. Plasmalogens contains a vinyl–ether bond that
makes plasmalogens susceptible to oxidative attack.
They may therefore have a crucial role as endogenous
antioxidants during states of increased oxidative burden,
especially in relation to membrane properties as these
lipids are structural components of cellular membranes
[31–33]. The hepatic level of the plasmalogen PC P was
decreased by nearly 50 % in FO fed, but not changed in
KO fed mice (Fig. 1b). The lower levels of plasmalogens
in the FO mice may indicate a larger increase in oxida-
tive stress compared to the KO mice.
Also for the hepatic and brain levels of CE differences
between the intervention groups were observed. The
hepatic levels of CE are determined by the cholesterol
esterification reaction and secretion. Individual FAs
interact with cholesterol to regulate both the output and
uptake of sterol by the liver, and these effects are
dependent on the esterification reaction [34]. This reac-
tion is enhanced by unsaturated FA such as 18:1 and
18:2, and the hepatic abundance of these fatty acids is
higher in the KO fed compared to the FO fed mice, con-
sistent with the higher level of total CE in the KO mice
(Figs. 2c and 6). KO and FO were similarly potent in
regulation of CE 20:5 and 22:6 in brain and liver. The in-
crease in CE 20:5 concentration in the liver was nearly
10 fold while the increase in CE 22:6 was much smaller.
In the brain the specificity was opposite with the largest
increase in CE 22:6. FO decreased CE 18:1 in the brain
but not in the liver, while CE 20:4 was decreased in both
tissues (Fig. 6). Two acyl-coenzyme A:cholesterol acyl-
transferases (ACAT1 and ACAT2) with different tissue
expression catalyze the esterification of cholesterol to
fatty acids [35]. ACAT2 expression is restricted to
hepatocytes and enterocytes while ACAT1 is widely
expressed. The different regulation of CE in liver and
brain may be due to different fatty acid specificities of
the two ACAT enzymes. DHA is substrate for ACAT1,
which also inhibits CE formation from 18:1 (in line with
the decrease in CE 18:1 in brain) [36]. However, contra-
dictory to our observation that total CE is increased in
KO (and slightly in FO), it was reported that both EPA
and DHA decreased synthesis and secretion of CE in
rat hepatocytes [37]. Taken together, the sum effect of
KO and FO is likely to be due to changes in synthesis
(substrate specificity/ inhibition), secretion and possibly
also differences in transcriptional regulation of ACAT1
and ACAT2 by long chain PUFAs [38].Conclusion
This study has demonstrated that the molecular struc-
ture of omega-3 fatty acid esters may affect the distribu-
tion and fatty acid content of some of the major, and
importantly also some of the minor, hepatic and brain
lipids. Changes in the plasma lipid levels do not seem to
be dependent on the source of the omega-3 fatty acids.
However, considering the observed changes in the hep-
atic sphingolipid levels and fatty acid composition, espe-
cially the level of 20:4, the direction of change is always
larger in the KO fed compared to the FO fed mice. The
data are consistent with the hypothesis that KO has a
stronger anti-inflammatory action and enhances insulin
sensitivity more potently than FO.
Methods
Animals and diets
Nine to ten week old male C57BL/6 J mice were fed ei-
ther a high-fat diet (HF) containing 24 % (wt/wt) fat
(21.3 % lard and 2.3 % soy oil, n = 9), HF diet supple-
mented with FO (EPAX 6000 TG®, a generous gift of
Epax A/S, Ålesund, Norway) (15.7 % lard, 2.3 % soy oil
and 5.8 % FO, n = 6) or the HF diet supplemented with
KO (Superba™, a generous gift of Aker BioMarine Ant-
arctic AS, Oslo, Norway) (15.7 % lard, 2.3 % soy oil and
5.7 % KO, n = 6) and water ad libitum for 6 weeks. Diets
were packaged in airtight bags and freeze stored until
use to prevent lipid oxidation. Mice were housed in
groups of three per cage at a constant temperature of
22 ± 2 °C and a light/dark cycle of 12/12 h. Body weights
of the animals were measured approximately every sev-
enth day and food intake was measured three times in the
beginning of the 6-week study to optimize the food sup-
ply. At the end of study animals were fasted overnight,
anesthetized with 2 % isoflurane (Schering-Plough, UK)
and blood was collected by heart puncture. After
collection all tissue samples were immediately frozen in
liquid nitrogen and stored at −80 °C until further ana-
lysis. The animal experiments were carried out with
ethical permission obtained from the Norway State
Board for Biological Experiments and followed the
Norwegian Research Councils ethical guidelines.
Fatty acid analysis of diet composition
Lipids were extracted and methyl esters were obtained
as previously described [39, 40]. After extraction into an
organic solvent, fatty acid methyl esters were analyzed
by gas–liquid chromatography. The gas chromatograph
(GC 8000 TOP Finnigan, USA) was equipped with a
programmed temperature vaporization injector, flame-
ionization detector, AS 800 autosampler, and a fused sil-
ica capillary column coated with dimethylpolysiloxane
stationary phase, DB1-ms (J & W Scientific, USA).
Hydrogen was used as carrier gas. Column temperature
Skorve et al. Lipids in Health and Disease  (2015) 14:88 Page 11 of 12was programmed from 110 to 310 °C with a gradient
2.5 °C/min. GC signal was acquired and evaluated with
Chromeleon software (Dionex, USA). Peaks were iden-
tified by means of known FA standards and by means
of mass spectra, obtained by GC/MS analysis (GCQ,
Finnigan, USA) on the same column. Internal standard
C21:0 was used for quantitation after calibration with
known mixtures of FA standards.Lipidomic analysis
The tissue samples were weighted, pulverized with
CP02 CryoPrep Dry Pulverization System (Covaris), and
resuspended in ice-cold methanol containing 0.1 % butyl-
hydroxytoluene (BHT) at a concentration of 100 mg/ml.
The homogenized samples were stored at −80 °C prior to
lipid extraction and analysis. Lipids were extracted from
liver and brain homogenates using a modified Folch lipid
extraction procedure [41] and in shotgun and TAG lipido-
mics lipid extracts were analyzed on a hybrid triple quad-
rupole/linear ion trap mass spectrometer (QTRAP 5500)
equipped with a robotic nanoflow ion source (NanoMate
HD) according to Ståhlman et al. [42]. Molecular lipids
were analyzed in both positive and negative ion modes
using multiple precursor ion scanning (MPIS) based
methods [43, 44]. Targeted sphingolipid lipidomics was
performed on a hybrid triple quadrupole/linear ion trap
mass spectrometer (4000 QTRAP) equipped with an
ultra high pressure liquid chromatography (UHPLC)
system (CTC HTC PAL autosampler and Rheos Allegro
pump) using multiple reaction monitoring (MRM) –
based method [45].Statistical analyses
Statistical analyses were performed using SAS version
9.4. Log-transformation was applied to approximate
log-normality of the data and unpaired Student t-test
was performed to compare the differences between
the study groups. Percentage differences and their
significances were calculated with pairwise compari-
sons. Presented differences are the relative differences
between group averages in non-log scale. In the stat-
istical analyses p < 0.01 was considered significantly
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